Tokyo Tape
Sign in
← H.U. Group Holdings

Annual report

4544.TEDINET S100YB46
Period2025-04-01 → 2026-03-31
Filed2026-06-15
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 154
MetricValuePeriodScopeSource row
Revenue¥247.4bn2025-04-01 → 2026-03-31Cons.Net sales
Revenue¥243.0bn2024-04-01 → 2025-03-31Cons.Net sales
Revenue¥236.9bn2023-04-01 → 2024-03-31vCons.Net sales (5-year summary)
Revenue¥260.9bn2022-04-01 → 2023-03-31vCons.Net sales (5-year summary)
Revenue¥272.9bn2021-04-01 → 2022-03-31vCons.Net sales (5-year summary)
Operating income¥4.8bn2025-04-01 → 2026-03-31Cons.Operating income
Operating income¥2.6bn2024-04-01 → 2025-03-31Cons.Operating income
Ordinary income¥2.8bn2025-04-01 → 2026-03-31Cons.Ordinary income
Ordinary income¥4.7bn2024-04-01 → 2025-03-31Cons.Ordinary income
Ordinary income−¥7.2bn2023-04-01 → 2024-03-31vCons.Ordinary income loss (5-year summary)
Ordinary income¥22.0bn2022-04-01 → 2023-03-31vCons.Ordinary income loss (5-year summary)
Ordinary income¥47.4bn2021-04-01 → 2022-03-31vCons.Ordinary income loss (5-year summary)
Profit before tax¥8.6bn2025-04-01 → 2026-03-31Cons.Income before income taxes
Profit before tax¥3.2bn2024-04-01 → 2025-03-31Cons.Income before income taxes
Net income (owners)¥6.8bn2025-04-01 → 2026-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.8bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥7.6bn2023-04-01 → 2024-03-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥15.7bn2022-04-01 → 2023-03-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥29.6bn2021-04-01 → 2022-03-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income¥6.7bn2025-04-01 → 2026-03-31Cons.Profit loss
Net income¥2.7bn2024-04-01 → 2025-03-31Cons.Profit loss
Total assets¥267.5bnat 2026-03-31Cons.Assets
Total assets¥279.6bnat 2025-03-31Cons.Assets
Total assets¥290.8bnat 2024-03-31vCons.Total assets (5-year summary)
Total assets¥297.9bnat 2023-03-31vCons.Total assets (5-year summary)
Total assets¥286.6bnat 2022-03-31vCons.Total assets (5-year summary)
Total liabilities¥130.0bnat 2026-03-31Cons.Liabilities
Total liabilities¥142.3bnat 2025-03-31Cons.Liabilities
Net assets / equity¥137.5bnat 2026-03-31Cons.Net assets
Net assets / equity¥137.3bnat 2025-03-31Cons.Net assets
Net assets / equity¥142.5bnat 2024-03-31vCons.Net assets
Net assets / equity¥150.0bnat 2023-03-31vCons.Net assets (5-year summary)
Net assets / equity¥140.2bnat 2022-03-31vCons.Net assets (5-year summary)
Cash and deposits¥48.1bnat 2026-03-31Cons.Cash and deposits
Cash and deposits¥40.9bnat 2025-03-31Cons.Cash and deposits
Cash & equivalents¥48.1bnat 2026-03-31Cons.Cash and cash equivalents
Cash & equivalents¥40.9bnat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥39.9bnat 2024-03-31vCons.Cash and cash equivalents
Cash & equivalents¥44.2bnat 2023-03-31vCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥46.5bnat 2022-03-31vCons.Cash and cash equivalents (5-year summary)
Operating cash flow¥21.6bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥22.0bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥16.6bn2023-04-01 → 2024-03-31vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥32.5bn2022-04-01 → 2023-03-31vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥55.2bn2021-04-01 → 2022-03-31vCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow¥11.3bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥16.0bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥16.1bn2023-04-01 → 2024-03-31vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥29.6bn2022-04-01 → 2023-03-31vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥30.9bn2021-04-01 → 2022-03-31vCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥26.4bn2025-04-01 → 2026-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.3bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.8bn2023-04-01 → 2024-03-31vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥5.8bn2022-04-01 → 2023-03-31vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥21.7bn2021-04-01 → 2022-03-31vCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥121.522025-04-01 → 2026-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥48.62024-04-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-132.772023-04-01 → 2024-03-31vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥275.522022-04-01 → 2023-03-31vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥519.552021-04-01 → 2022-03-31vCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥121.422025-04-01 → 2026-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥275.52022-04-01 → 2023-03-31vCons.Diluted earnings per share (5-year summary)
EPS (diluted)¥519.422021-04-01 → 2022-03-31vCons.Diluted earnings per share (5-year summary)
Net assets per share¥2,474.75at 2026-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥2,411.4at 2025-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥2,506.5at 2024-03-31vCons.Net assets per share (5-year summary)
Net assets per share¥2,635.26at 2023-03-31vCons.Net assets per share (5-year summary)
Net assets per share¥2,463.33at 2022-03-31vCons.Net assets per share (5-year summary)
Equity ratio51.3%at 2026-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio49.0%at 2025-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio49.0%at 2024-03-31vCons.Equity to asset ratio (5-year summary)
Equity ratio50.3%at 2023-03-31vCons.Equity to asset ratio (5-year summary)
Equity ratio48.9%at 2022-03-31vCons.Equity to asset ratio (5-year summary)
ROE5.0%2025-04-01 → 2026-03-31Cons.Rate of return on equity (5-year summary)
ROE2.0%2024-04-01 → 2025-03-31Cons.Rate of return on equity (5-year summary)
ROE10.8%2022-04-01 → 2023-03-31vCons.Rate of return on equity (5-year summary)
ROE23.2%2021-04-01 → 2022-03-31vCons.Rate of return on equity (5-year summary)
Employees5,157at 2026-03-31Cons.Number of employees
Employees5,444at 2025-03-31Cons.Number of employees
Employees5,295at 2024-03-31vCons.Number of employees
Employees5,437at 2023-03-31vCons.Number of employees
Employees5,444at 2022-03-31vCons.Number of employees
Revenue¥16.8bn2025-04-01 → 2026-03-31StandaloneOperating revenue1
Revenue¥30.1bn2024-04-01 → 2025-03-31StandaloneOperating revenue1
Revenue¥23.4bn2023-04-01 → 2024-03-31vStandaloneOperating revenue1 (5-year summary)
Revenue¥24.7bn2022-04-01 → 2023-03-31vStandaloneOperating revenue1 (5-year summary)
Revenue¥17.1bn2021-04-01 → 2022-03-31vStandaloneOperating revenue1 (5-year summary)
Operating income¥6.5bn2025-04-01 → 2026-03-31StandaloneOperating income
Operating income¥18.7bn2024-04-01 → 2025-03-31StandaloneOperating income
Ordinary income¥6.8bn2025-04-01 → 2026-03-31StandaloneOrdinary income
Ordinary income¥19.9bn2024-04-01 → 2025-03-31StandaloneOrdinary income
Ordinary income¥8.4bn2023-04-01 → 2024-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥12.4bn2022-04-01 → 2023-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥4.2bn2021-04-01 → 2022-03-31vStandaloneOrdinary income loss (5-year summary)
Profit before tax¥7.5bn2025-04-01 → 2026-03-31StandaloneIncome before income taxes
Profit before tax¥20.1bn2024-04-01 → 2025-03-31StandaloneIncome before income taxes
Net income¥7.9bn2025-04-01 → 2026-03-31StandaloneProfit loss
Net income¥22.1bn2024-04-01 → 2025-03-31StandaloneProfit loss
Net income¥9.7bn2023-04-01 → 2024-03-31vStandaloneNet income loss (5-year summary)
Net income¥12.9bn2022-04-01 → 2023-03-31vStandaloneNet income loss (5-year summary)
Net income¥5.9bn2021-04-01 → 2022-03-31vStandaloneNet income loss (5-year summary)
Total assets¥169.1bnat 2026-03-31StandaloneAssets
Total assets¥171.4bnat 2025-03-31StandaloneAssets
Total assets¥178.2bnat 2024-03-31vStandaloneTotal assets (5-year summary)
Total assets¥182.4bnat 2023-03-31vStandaloneTotal assets (5-year summary)
Total assets¥173.7bnat 2022-03-31vStandaloneTotal assets (5-year summary)
Total liabilities¥93.2bnat 2026-03-31StandaloneLiabilities
Total liabilities¥91.2bnat 2025-03-31StandaloneLiabilities
Net assets / equity¥75.9bnat 2026-03-31StandaloneNet assets
Net assets / equity¥80.2bnat 2025-03-31StandaloneNet assets
Net assets / equity¥66.7bnat 2024-03-31vStandaloneNet assets
Net assets / equity¥63.1bnat 2023-03-31vStandaloneNet assets (5-year summary)
Net assets / equity¥58.8bnat 2022-03-31vStandaloneNet assets (5-year summary)
Cash and deposits¥43.9bnat 2026-03-31StandaloneCash and deposits
Cash and deposits¥36.3bnat 2025-03-31StandaloneCash and deposits
EPS (basic)¥140.272025-04-01 → 2026-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥388.422024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥170.42023-04-01 → 2024-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥225.982022-04-01 → 2023-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥103.082021-04-01 → 2022-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥140.162025-04-01 → 2026-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥170.392023-04-01 → 2024-03-31vStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥225.972022-04-01 → 2023-03-31vStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥103.052021-04-01 → 2022-03-31vStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥1252025-04-01 → 2026-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1252024-04-01 → 2025-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1252023-04-01 → 2024-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥1252022-04-01 → 2023-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥1252021-04-01 → 2022-03-31vStandaloneDividend paid per share (5-year summary)
Net assets per share¥1,366.17at 2026-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,409.12at 2025-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,172.79at 2024-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥1,108.11at 2023-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥1,032.83at 2022-03-31vStandaloneNet assets per share (5-year summary)
Equity ratio44.8%at 2026-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio46.7%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio37.4%at 2024-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio34.6%at 2023-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio33.8%at 2022-03-31vStandaloneEquity to asset ratio (5-year summary)
ROE10.1%2025-04-01 → 2026-03-31StandaloneRate of return on equity (5-year summary)
ROE30.1%2024-04-01 → 2025-03-31StandaloneRate of return on equity (5-year summary)
ROE14.9%2023-04-01 → 2024-03-31vStandaloneRate of return on equity (5-year summary)
ROE21.1%2022-04-01 → 2023-03-31vStandaloneRate of return on equity (5-year summary)
ROE9.9%2021-04-01 → 2022-03-31vStandaloneRate of return on equity (5-year summary)
Shares issued57,492,322at 2026-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued57,473,822at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued57,473,822at 2024-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued57,471,867at 2023-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued57,446,657at 2022-03-31vStandaloneTotal number of issued shares (5-year summary)
Employees351at 2026-03-31StandaloneNumber of employees
Employees339at 2025-03-31StandaloneNumber of employees
Employees400at 2024-03-31vStandaloneNumber of employees
Employees392at 2023-03-31vStandaloneNumber of employees
Employees330at 2022-03-31vStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 72
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2025-04-01 → 2026-03-31¥570m
Reconciling Itemsreconcilingdepreciation2025-04-01 → 2026-03-31¥1.2bn
Reconciling Itemsreconcilingrevenue2025-04-01 → 2026-03-31−¥4.7bn
Reconciling Itemsreconcilingrevenue intersegment2025-04-01 → 2026-03-31−¥4.7bn
Reconciling Itemsreconcilingsegment assetsat 2026-03-31¥43.0bn
Reconciling Itemsreconcilingsegment profit2025-04-01 → 2026-03-31−¥6.1bn
Clinical Lab Testing Businessreportable segmentcapex2025-04-01 → 2026-03-31¥3.9bn
Clinical Lab Testing Businessreportable segmentdepreciation2025-04-01 → 2026-03-31¥13.6bn
Clinical Lab Testing Businessreportable segmentemployeesat 2026-03-312042 pure
Clinical Lab Testing Businessreportable segmentrevenue2025-04-01 → 2026-03-31¥157.6bn
Clinical Lab Testing Businessreportable segmentrevenue external2025-04-01 → 2026-03-31¥157.3bn
Clinical Lab Testing Businessreportable segmentrevenue intersegment2025-04-01 → 2026-03-31¥308m
Clinical Lab Testing Businessreportable segmentsegment assetsat 2026-03-31¥102.3bn
Clinical Lab Testing Businessreportable segmentsegment profit2025-04-01 → 2026-03-31¥31m
In Vitro Diagnostics Businessreportable segmentcapex2025-04-01 → 2026-03-31¥2.0bn
In Vitro Diagnostics Businessreportable segmentdepreciation2025-04-01 → 2026-03-31¥5.1bn
In Vitro Diagnostics Businessreportable segmentemployeesat 2026-03-311206 pure
In Vitro Diagnostics Businessreportable segmentrevenue2025-04-01 → 2026-03-31¥65.0bn
In Vitro Diagnostics Businessreportable segmentrevenue external2025-04-01 → 2026-03-31¥60.7bn
In Vitro Diagnostics Businessreportable segmentrevenue intersegment2025-04-01 → 2026-03-31¥4.3bn
In Vitro Diagnostics Businessreportable segmentsegment assetsat 2026-03-31¥111.3bn
In Vitro Diagnostics Businessreportable segmentsegment profit2025-04-01 → 2026-03-31¥9.1bn
Sterilization And Related Servicesreportable segmentcapex2025-04-01 → 2026-03-31¥1.2bn
Sterilization And Related Servicesreportable segmentdepreciation2025-04-01 → 2026-03-31¥1.2bn
Sterilization And Related Servicesreportable segmentemployeesat 2026-03-31943 pure
Sterilization And Related Servicesreportable segmentrevenue2025-04-01 → 2026-03-31¥29.5bn
Sterilization And Related Servicesreportable segmentrevenue external2025-04-01 → 2026-03-31¥29.3bn
Sterilization And Related Servicesreportable segmentrevenue intersegment2025-04-01 → 2026-03-31¥122m
Sterilization And Related Servicesreportable segmentsegment assetsat 2026-03-31¥10.9bn
Sterilization And Related Servicesreportable segmentsegment profit2025-04-01 → 2026-03-31¥1.8bn
—segment totalcapex2025-04-01 → 2026-03-31¥7.0bn
—segment totaldepreciation2025-04-01 → 2026-03-31¥20.0bn
—segment totalemployeesat 2026-03-314191 pure
—segment totalrevenue2025-04-01 → 2026-03-31¥252.0bn
—segment totalrevenue external2025-04-01 → 2026-03-31¥247.4bn
—segment totalrevenue intersegment2025-04-01 → 2026-03-31¥4.7bn
—segment totalsegment assetsat 2026-03-31¥224.5bn
—segment totalsegment profit2025-04-01 → 2026-03-31¥10.8bn
Reconciling Itemsreconcilingcapex2024-04-01 → 2025-03-31¥500m
Reconciling Itemsreconcilingdepreciation2024-04-01 → 2025-03-31¥1.4bn
Reconciling Itemsreconcilingrevenue2024-04-01 → 2025-03-31−¥5.0bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2025-03-31−¥5.0bn
Reconciling Itemsreconcilingsegment assetsat 2025-03-31¥48.9bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2025-03-31−¥5.8bn
Clinical Lab Testing Businessreportable segmentcapex2024-04-01 → 2025-03-31¥6.3bn
Clinical Lab Testing Businessreportable segmentdepreciation2024-04-01 → 2025-03-31¥12.2bn
Clinical Lab Testing Businessreportable segmentrevenue2024-04-01 → 2025-03-31¥153.5bn
Clinical Lab Testing Businessreportable segmentrevenue external2024-04-01 → 2025-03-31¥153.0bn
Clinical Lab Testing Businessreportable segmentrevenue intersegment2024-04-01 → 2025-03-31¥471m
Clinical Lab Testing Businessreportable segmentsegment assetsat 2025-03-31¥108.6bn
Clinical Lab Testing Businessreportable segmentsegment profit2024-04-01 → 2025-03-31−¥4.6bn
In Vitro Diagnostics Businessreportable segmentcapex2024-04-01 → 2025-03-31¥3.4bn
In Vitro Diagnostics Businessreportable segmentdepreciation2024-04-01 → 2025-03-31¥5.0bn
In Vitro Diagnostics Businessreportable segmentrevenue2024-04-01 → 2025-03-31¥65.0bn
In Vitro Diagnostics Businessreportable segmentrevenue external2024-04-01 → 2025-03-31¥60.5bn
In Vitro Diagnostics Businessreportable segmentrevenue intersegment2024-04-01 → 2025-03-31¥4.5bn
In Vitro Diagnostics Businessreportable segmentsegment assetsat 2025-03-31¥108.0bn
In Vitro Diagnostics Businessreportable segmentsegment profit2024-04-01 → 2025-03-31¥11.3bn
Sterilization And Related Servicesreportable segmentcapex2024-04-01 → 2025-03-31¥1.3bn
Sterilization And Related Servicesreportable segmentdepreciation2024-04-01 → 2025-03-31¥1.7bn
Sterilization And Related Servicesreportable segmentrevenue2024-04-01 → 2025-03-31¥29.6bn
Sterilization And Related Servicesreportable segmentrevenue external2024-04-01 → 2025-03-31¥29.5bn
Sterilization And Related Servicesreportable segmentrevenue intersegment2024-04-01 → 2025-03-31¥46m
Sterilization And Related Servicesreportable segmentsegment assetsat 2025-03-31¥14.2bn
Sterilization And Related Servicesreportable segmentsegment profit2024-04-01 → 2025-03-31¥1.8bn
—segment totalcapex2024-04-01 → 2025-03-31¥11.0bn
—segment totaldepreciation2024-04-01 → 2025-03-31¥18.9bn
—segment totalrevenue2024-04-01 → 2025-03-31¥248.0bn
—segment totalrevenue external2024-04-01 → 2025-03-31¥243.0bn
—segment totalrevenue intersegment2024-04-01 → 2025-03-31¥5.0bn
—segment totalsegment assetsat 2025-03-31¥230.7bn
—segment totalsegment profit2024-04-01 → 2025-03-31¥8.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,994
ItemContextValueUnit
Commission fee sgaPrior1YearDuration13632000000JPY
Commission fee sgaCurrentYearDuration13910000000JPY
Research and development expenses sgaPrior1YearDuration10894000000JPY
Research and development expenses sgaCurrentYearDuration11171000000JPY
Research and development expenses sgaPrior1YearDuration10894000000JPY
Research and development expenses sgaCurrentYearDuration11171000000JPY
Revenues from external customersPrior1YearDuration_jpcrp030000-asr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember153014000000JPY
Revenues from external customersPrior1YearDuration_jpcrp030000-asr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember60492000000JPY
Revenues from external customersPrior1YearDuration_jpcrp030000-asr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember29518000000JPY
Revenues from external customersPrior1YearDuration_ReportableSegmentsMember243025000000JPY
Revenues from external customersPrior1YearDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YearDuration243025000000JPY
Transactions with other segmentsPrior1YearDuration_jpcrp030000-asr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember471000000JPY
Transactions with other segmentsPrior1YearDuration_jpcrp030000-asr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember4478000000JPY
Transactions with other segmentsPrior1YearDuration_jpcrp030000-asr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember46000000JPY
Transactions with other segmentsPrior1YearDuration_ReportableSegmentsMember4996000000JPY
Transactions with other segmentsPrior1YearDuration_ReconcilingItemsMember-4996000000JPY
Transactions with other segmentsPrior1YearDuration－JPY
Net salesPrior1YearDuration_jpcrp030000-asr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember153485000000JPY
Net salesPrior1YearDuration_jpcrp030000-asr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember64971000000JPY
Net salesPrior1YearDuration_jpcrp030000-asr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember29565000000JPY
Net salesPrior1YearDuration_ReportableSegmentsMember248022000000JPY
Net salesPrior1YearDuration_ReconcilingItemsMember-4996000000JPY
Net salesPrior1YearDuration243025000000JPY
Operating incomePrior1YearDuration_jpcrp030000-asr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember-4638000000JPY
Operating incomePrior1YearDuration_jpcrp030000-asr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember11345000000JPY
Operating incomePrior1YearDuration_jpcrp030000-asr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember1777000000JPY
Operating incomePrior1YearDuration_ReportableSegmentsMember8484000000JPY
Operating incomePrior1YearDuration_ReconcilingItemsMember-5844000000JPY
Operating incomePrior1YearDuration2640000000JPY
AssetsPrior1YearInstant_jpcrp030000-asr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember108603000000JPY
AssetsPrior1YearInstant_jpcrp030000-asr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember107957000000JPY
AssetsPrior1YearInstant_jpcrp030000-asr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember14151000000JPY
AssetsPrior1YearInstant_ReportableSegmentsMember230712000000JPY
AssetsPrior1YearInstant_ReconcilingItemsMember48869000000JPY
AssetsPrior1YearInstant279582000000JPY
Depreciation segment informationPrior1YearDuration_jpcrp030000-asr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember12245000000JPY
Depreciation segment informationPrior1YearDuration_jpcrp030000-asr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember4950000000JPY
Depreciation segment informationPrior1YearDuration_jpcrp030000-asr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember1713000000JPY
Depreciation segment informationPrior1YearDuration_ReportableSegmentsMember18909000000JPY
Depreciation segment informationPrior1YearDuration_ReconcilingItemsMember1355000000JPY
Depreciation segment informationPrior1YearDuration20264000000JPY
Amortization of goodwill sgaPrior1YearDuration_jpcrp030000-asr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember43000000JPY
Amortization of goodwill sgaPrior1YearDuration_jpcrp030000-asr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember397000000JPY
Amortization of goodwill sgaPrior1YearDuration_jpcrp030000-asr_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember40000000JPY
Amortization of goodwill sgaPrior1YearDuration_ReportableSegmentsMember482000000JPY
Amortization of goodwill sgaPrior1YearDuration_ReconcilingItemsMember－JPY
Amortization of goodwill sgaPrior1YearDuration482000000JPY
Investments in entities accounted for using equity methodPrior1YearDuration_jpcrp030000-asr_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember1381000000JPY
Investments in entities accounted for using equity methodPrior1YearDuration_jpcrp030000-asr_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2025-03-31pass
balance sheet identityconsolidated 2026-03-31pass
balance sheet identitynon_consolidated 2025-03-31pass
balance sheet identitynon_consolidated 2026-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2025-03-31pass
statement vs summary · net assetsconsolidated 2026-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · net assetsnon_consolidated 2026-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2026-03-31pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2026-03-31pass
statement vs summary · revenueconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenueconsolidated 2025-04-01/2026-03-31pass
statement vs summary · revenuenon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · revenuenon_consolidated 2025-04-01/2026-03-31pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2026-03-31pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass
statement vs summary · total assetsnon_consolidated 2026-03-31pass